Stories about Colonization

Subscribe to Colonization

20.08.2020 – 16:21

Jennewein Biotechnologie GmbH
US Customs rules in favor of Jennewein Biotechnologie regarding importation of 2'-Fucosyllactose

RHEINBREITBACH, Germany (ots) - Jennewein Biotechnologie GmbH the leading manufacturer of human milk oligosaccharides (HMOs) in the world, announced today that the Intellectual Property Rights Branch, Regulations and Rulings, U.S. Customs and Border Protection issued a Ruling Letter which asserts that the HMO 2'-fucosyllactose (2'-FL) being produced by Jennewein ...

more
29.07.2020 – 15:00

Jennewein Biotechnologie GmbH
Jennewein Biotechnologie GmbH announces the foundation of Jennewein Biotech Corp. USA

Rheinbreitbach (ots) - Jennewein Biotechnologie GmbH, a market leading and science-based company for developing and producing human milk oligosaccharides (HMOs) and rare monosaccharides, announced today that it has established its subsidiary in the USA. Jennewein Biotech USA Corporation, a Delaware Corporation, utilizing warehouses in Chicago, IL and Columbus, OH, will ...

more
27.05.2020 – 11:00

Jennewein Biotechnologie GmbH
Jennewein publishes new results on the norovirus-inhibiting effect of complex oligosaccharides

Rheinbreitbach (ots) - Jennewein Biotechnologie GmbH today announces the publication of the latest results from its norovirus research program in the Journal of Biotechnology. Breast-fed infants are less likely than bottle-fed infants to contract norovirus infections, and earlier work has indicated a link between this protective effect and human milk oligosaccharides ...

more
20.05.2020 – 15:09

Jennewein Biotechnologie GmbH
Supply of Key Ingredient in advanced infant formula by Jennewein is secured

Rheinbreitbach (ots) - Jennewein Biotechnologie GmbH, a worldwide leading manufacturer of human milk oligosaccharides (HMOs) announces today that the U.S. International Trade Commission (ITC) issued on May 19, 2020 a Final Determination finding that one of Jennewein's advanced bacterial production strains for producing 2'-fucosyllactose (2'-FL) does not infringe ...

more
03.03.2020 – 07:00

ACTP e. V.

World sensation: The Spix's Macaw is back /Extinct parrot species is being resettled in Brazil

more
10.01.2020 – 12:00

Jennewein Biotechnologie GmbH
Jennewein Biotechnologie GmbH enforces its patents in the field of human milk oligosaccharides against Nestlé in Germany

Rheinbreitbach (ots) - Jennewein Biotechnologie GmbH filed a patent infringement suit with the regional court in Mannheim on January 09, 2020 against Nestlé Nutrition GmbH and its holding company Nestlé Deutschland AG. Nestlé offers its infant formula Beba Supreme which contains two human milk oligosaccharides - ...

more
08.01.2020 – 17:00

Jennewein Biotechnologie GmbH
Publication of a toxicological study: a milestone for Jennewein Biotechnologie for the GRAS approval of the HMO-mix

Rheinbreitbach (ots) - Jennewein Biotechnology announces another milestone in the Worldwide approval of a new product generation, the "HMO-Mix". The data of the toxicological study, with the title "A Safety Evaluation of Mixed Human Milk Oligosaccharides in Rats", was recently accepted for publication by the ...

more
25.11.2019 – 10:13

Jennewein Biotechnologie GmbH
Jennewein Biotechnologie obtains US-FDA GRAS status on alternative 2'-fucosyllactose fermentation strain

Rheinbreitbach (ots) - Jennewein Biotechnologie GmbH, Rheinbreitbach, the leading manufacturer of human milk oligosaccharides (HMOs), announces that the U.S. Food and Drug Administration (FDA) issued a "no question" response letter to Jennewein's supplement of its GRAS Notice GRN571, thereby acknowledging that the ...

more
25.11.2019 – 10:02

Jennewein Biotechnologie GmbH
Jennewein Biotechnologie sues Glycom for patent infringement in Denmark

Rheinbreitbach (ots) - Jennewein Biotechnologie develops fermentative processes for manufacturing of human milk oligosaccharides (HMOs) cost efficiently in an industrial scale since 2005 to make these special sugars available for affordably priced infant formula and other uses in food. Jennewein Biotechnologie was the first commercial vendor of HMOs, and brought the ...

more
11.09.2019 – 17:00

Jennewein Biotechnologie GmbH
Administrative Law Judge issues ruling in patent dispute concerning 2'-FL production and beta-galactosidase activity

Rheinbreitbach (ots) - On September 09, 2019, Administrative Law Judge Cameron Elliot of the US International Trade Commission issued an Initial Determination finding that one of the bacterial strains used by Jennewein Biotechnologie to make 2'-fucosyllactose (2'-FL) infringes a patent owned by Glycosyn LLC. In the ...

more
01.07.2019 – 11:10

Brenntag AG
Brenntag EMEA distributes Borregaard's SoftAcid® and Neubacid® Soft products to animal feed industry

Dear all, Please find attached Brenntag EMEA's press release regarding the agreement with Borregaard on the purchase, licence production and distribution of the SoftAcid® and Neubacid® Soft products to the European animal ...
Find more information on our website.

more
05.07.2018 – 12:00

Jennewein Biotechnologie GmbH
Jennewein Biotechnologie to build new R&D centre for synthetic organisms and microbiome research in Bonn, Germany

Rheinbreitbach (ots) - Jennewein Biotechnologie announces that on June 15, 2018, it signed a long-term lease for a 1000-m2 plot of land on Mildred-Scheel-Straße, Bonn Bad Godesberg, which will be the site of a new R&D centre for microbiome research and designer microorganisms. "The relocation of part of our ...

more

1